Previous 10 | Next 10 |
UroGen is using its proprietary reverse thermal gel technology to pioneer a line of therapies for upper urinary tract cancers that are substantially better than current options. Jelmyto is already on the market with estimated peak sales around $375 million, but UGN-102 is about to sta...
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021: Cowen 41 st Annua...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event. For further details see: Urogen Pharma (URGN) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
UroGen Pharma (URGN) and The University of Texas MD Anderson Cancer Center announce a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladde...
Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and uro...
UroGen's Jelmyto, approved April 2020 for LG-UTUC, has a J code effective 1/1/2021 allowing for dramatically more convenient coding & reimbursement. Revenues should be about $115,000/patient as labelled (6 doses). Jelmyto's clinical, quality of life & healthcare economic value...
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the virtual 39 th Annu...
Clinically Meaningful Response Underscores Potential for Jelmyto to Become New Standard of Care for Patients with Low-Grade Upper Tract Urothelial Cancer Of the 58% of Patients who Achieved a Complete Response, 12-Month Durability of Response Estimated at 81.8% by Kaplan-Mei...
65% Complete Response Rate at Three Months Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response was Not Reached Treatment with UGN-102 was Generally Well Tolerated, with M...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and produc...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...